Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 206

Similar articles for PubMed (Select 14585937)

1.

Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators.

N Engl J Med. 2003 Oct 30;349(18):1695-702. Erratum in: N Engl J Med. 2004 Jan 22;350(4):423.

2.

[Prevention of venous thromboembolic events by fondaparinux 2.5mg in patients hospitalized for an acute medical illness. ArchiMed Study].

Leroyer C, Mahé I, Daurès JP, Quéré I, Aubin C, Compagnon A, Doussaint J, Schück S, Pouchain D.

J Mal Vasc. 2015 Jun 4. pii: S0398-0499(15)00105-5. doi: 10.1016/j.jmv.2015.05.001. [Epub ahead of print] French.

PMID:
26051860
3.

Treatment of hemolysis with intravenous unfractionated heparin using an antifactor Xa-based monitoring protocol.

Adatya S, John R, Eckman PM.

J Thorac Cardiovasc Surg. 2015 May;149(5):1465-6. doi: 10.1016/j.jtcvs.2015.02.029. No abstract available.

PMID:
25983257
4.

Outpatient management eligibility criteria for patients who have acute symptomatic pulmonary embolism.

Yusen RD, Jiménez D.

Ann Am Thorac Soc. 2015 May;12(5):623-4. doi: 10.1513/AnnalsATS.201503-149ED. No abstract available.

PMID:
25965536
5.

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program.

Yamada N, Hirayama A, Maeda H, Sakagami S, Shikata H, Prins MH, Lensing AW, Kato M, Onuma J, Miyamoto Y, Iekushi K, Kajikawa M.

Thromb J. 2015 Jan 17;13:2. doi: 10.1186/s12959-015-0035-3. eCollection 2015.

6.

A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery.

Fuji T, Fujita S, Kawai Y, Abe Y, Kimura T, Fukuzawa M, Abe K, Tachibana S.

Thromb J. 2015 Jan 30;13(1):6. doi: 10.1186/s12959-014-0034-9. eCollection 2015.

7.

Fondaparinux in the initial and long-term treatment of venous thromboembolism.

Pesavento R, Amitrano M, Trujillo-Santos J, Di Micco P, Mangiacapra S, López-Jiménez L, Falgá C, García-Bragado F, Piovella C, Prandoni P, Monreal M; RIETE Investigators.

Thromb Res. 2015 Feb;135(2):311-7. doi: 10.1016/j.thromres.2014.11.032. Epub 2014 Dec 13.

PMID:
25543161
8.

Issues with monitoring of unfractionated heparin in cirrhosis.

Potze W, Lisman T.

Ther Drug Monit. 2015 Apr;37(2):279-80. doi: 10.1097/FTD.0000000000000132. No abstract available.

PMID:
25265256
9.

Systemic effects of subcutaneous heparin use in otolaryngology patients.

Blank SJ, Grindler DJ, Zerega J, Blinder M, Nussenbaum B.

Otolaryngol Head Neck Surg. 2014 Dec;151(6):967-71. doi: 10.1177/0194599814552055. Epub 2014 Sep 25.

PMID:
25257903
10.

FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events.

Ko RH, Michieli C, Lira JL, Young G.

Thromb Res. 2014 Sep;134(3):643-7. doi: 10.1016/j.thromres.2014.07.026. Epub 2014 Jul 23.

PMID:
25087891
11.

Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin.

Riess H, Becker LK, Melzer N, Harenberg J.

Blood Coagul Fibrinolysis. 2014 Dec;25(8):838-44. doi: 10.1097/MBC.0000000000000166.

PMID:
25004024
12.

The value of inhibitors of factor Xa for the treatment of pulmonary embolism.

Prandoni P, Temraz S, Barbar S, Pesavento R, Taher A.

Intern Emerg Med. 2014 Sep;9(6):617-22. doi: 10.1007/s11739-014-1085-4. Epub 2014 May 29.

PMID:
24871638
13.

Acute phase treatment of pulmonary embolism.

Chalikias G, Konstantinides S.

Curr Vasc Pharmacol. 2014 May;12(3):393-400. Review.

PMID:
24846228
14.

Impact of the efficacy of thrombolytic therapy on the mortality of patients with acute submassive pulmonary embolism: a meta-analysis.

Nakamura S, Takano H, Kubota Y, Asai K, Shimizu W.

J Thromb Haemost. 2014 Jul;12(7):1086-95. doi: 10.1111/jth.12608. Epub 2014 Jun 19.

15.

Fondaparinux Monitoring: Need for a Local Fondaparinux-Calibrated Anti-F actor Xa Assay.

Johnson PN, Benefield EC, Bui PY, Gausman JN, Marlar RA, Gessouroun MR.

J Pediatr Pharmacol Ther. 2013 Oct;18(4):318-9. doi: 10.5863/1551-6776-18.4.318. No abstract available.

16.

Fondaparinux in an obese child with heparin-induced thrombocytopenia and a history of renal failure.

Johnson PN, Benefield EC, Bui PY, Marlar RA, Gessouroun MR.

J Pediatr Pharmacol Ther. 2013 Oct;18(4):303-10. doi: 10.5863/1551-6776-18.4.303.

17.

Fibrinolysis for patients with intermediate-risk pulmonary embolism.

Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV; PEITHO Investigators.

N Engl J Med. 2014 Apr 10;370(15):1402-11. doi: 10.1056/NEJMoa1302097.

18.

Pulmonary thromboembolism in lung surgery: use of unfractionated heparin.

Yoshida J, Inoue M, Furugaki K, Oyama M, Oozono K.

Asian Cardiovasc Thorac Ann. 2014 Jan;22(1):46-8. doi: 10.1177/0218492313475672. Epub 2013 Oct 22.

PMID:
24585643
19.

Treatment of lower extremity superficial thrombophlebitis.

Di Nisio M, Middeldorp S.

JAMA. 2014 Feb 19;311(7):729-30. doi: 10.1001/jama.2014.520.

PMID:
24549553
20.

Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial.

Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Hernandez J.

J Thromb Haemost. 2014 Apr;12(4):459-68. doi: 10.1111/jth.12521.

PMID:
24484241
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk